Unknown

Dataset Information

0

The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers.


ABSTRACT: We aimed to characterise the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy males and explore the effect of food and formulation on the oral absorption of DRL-17822 in 4 phase I studies. DRL-17822 was dosed orally (2-1000 mg) in 2 different drug formulations (nanocrystal formulation and amorphous solid dispersion formulation) after either an overnight fast, or a low-fat, continental or high-fat breakfast. A 2-compartment model with 6 transit absorption compartments best characterised the data. Additionally, a strong interaction of food and formulation on bioavailability was observed and parsimoniously characterised in the model by binning combinations of food state and formulation with similar bio-availabilities. The final model adequately characterised the pharmacokinetic data of DRL-17822 in healthy males including the complex interaction of food and drug formulation. The amorphous solid dispersion formulation has a lower food effect on bioavailability compared with the nanocrystal formulation.

SUBMITTER: Goulooze SC 

PROVIDER: S-EPMC7495284 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers.

Goulooze Sebastiaan C SC   Kruithof Annelieke C AC   Alikunju Shanavas S   Gautam Anirudh A   Burggraaf Jacobus J   Kamerling Ingrid M C IMC   Stevens Jasper J  

British journal of clinical pharmacology 20200420 10


We aimed to characterise the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy males and explore the effect of food and formulation on the oral absorption of DRL-17822 in 4 phase I studies. DRL-17822 was dosed orally (2-1000 mg) in 2 different drug formulations (nanocrystal formulation and amorphous solid dispersion formulation) after either an overnight fast, or a low-fat, continental or high-fat breakfast. A 2-compartment model with 6 transit a  ...[more]

Similar Datasets

| S-EPMC10926053 | biostudies-literature
| S-EPMC7781808 | biostudies-literature
| S-EPMC7992283 | biostudies-literature
| S-EPMC4243901 | biostudies-literature
| S-EPMC2780279 | biostudies-literature
| S-EPMC8212751 | biostudies-literature
| S-EPMC6177703 | biostudies-other
| S-EPMC6586034 | biostudies-literature
| S-EPMC9292235 | biostudies-literature
| S-EPMC5610496 | biostudies-literature